Socks against side effects: simple stockings may shield nerves during chemo
NCT ID NCT07164950
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether wearing a compression stocking on one foot during antibody-drug conjugate (ADC) infusions can prevent peripheral neuropathy (nerve damage causing numbness or pain). Fifty-eight advanced cancer patients will wear a stocking on their left foot only, while the right foot serves as a comparison. Researchers will track nerve symptoms and quality of life over 24 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- medical-grade compression stocking (20-30 mmHg)
- What this could lead to
- If it works, this could offer a simple, non-drug way to prevent nerve damage from certain cancer treatments, improving quality of life.
- What could go wrong
- This is a small, early-phase trial (58 people) with a self-controlled design, so results may not apply broadly. The benefit may be modest or not statistically significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 58 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years Histologically or cytologically confirmed advanced malignancy (including but not limited to urothelial carcinoma) eligible for MMAE-containing ADC therapy (e.g., EV, DV, BV) * ECOG performance status 0-2 * No baseline peripheral neuropathy ≥ Grade 1 (CTCAE v5.0) * Stable tumor status without other neurotoxic drugs in the past 2 months * Adequate organ function (blood counts, liver and kidney function) per protocol * Expected survival ≥ 3 months * Ability and willingness to comply with study procedures and provide written informed consent Exclusion Criteria: * Poor compliance or inability to follow protocol * Pre-existing peripheral neuropathy ≥ Grade 1 from prior platinum/taxane treatment * Severe diabetes or peripheral vascular disease * Neurological disorders causing nerve compression (e.g., carpal tunnel syndrome, radiculopathy) * Severe psychiatric conditions (depression, bipolar disorder, substance abuse) * Active uncontrolled infections requiring systemic antibiotics/antifungals/antivirals (≥ CTCAE Grade 2) * Active hepatitis or significant liver dysfunction not meeting inclusion criteria * Renal failure requiring dialysis * Immunodeficiency or history of organ transplantation * Severe nausea, headache, fatigue, or other debilitating symptoms * Active tuberculosis or uncontrolled pleural/pericardial effusion/ascites * Hypersensitivity to monoclonal antibodies or study device components * Participation in other clinical trials within 4 weeks * Known bleeding or coagulation disorders or receiving thrombolytic therapy * Any other condition judged by the investigator to preclude safe participation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can intensified chemotherapy before surgery clear bladder tumors?
- First-in-Human trial asks whether HG381 is safe and tolerable in advanced solid tumors
- Custom-Built immune cells take aim at a notorious cancer mutation
- Chemo combo tested as backup for bladder cancer that outsmarts First-Line therapy
- Experimental injection SHR-7787 put to the test against advanced solid tumors
- Experimental biologic AWT020 put to the test in Hard-to-Treat cancers